Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

Insilico Medicine has entered into a strategic collaboration with SK Biopharmaceuticals to utilize its artificial intelligence platform for the discovery of new therapies for neuroimmune disorders. The deal includes up to $2.5 billion in potential milestone payments for Insilico, though the majority of these funds are contingent on the successful long-term development of clinical candidates.